Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial

BACKGROUND: Medications currently recommended for the treatment of Obsessive-Compulsive Disorder (OCD) usually decrease the severity of the symptoms by 20–30%; however, 40–60% of OCD patients do not achieve a satisfactory response. Our main objective was to investigate the effectiveness of memantine...

Descripción completa

Detalles Bibliográficos
Autores principales: Askari, Sanaz, Mokhtari, Saba, Shariat, Seyed Vahid, Shariati, Behnam, Yarahmadi, Masoomeh, Shalbafan, Mohammadreza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753835/
https://www.ncbi.nlm.nih.gov/pubmed/35022014
http://dx.doi.org/10.1186/s12888-021-03642-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753835/
https://www.ncbi.nlm.nih.gov/pubmed/35022014
http://dx.doi.org/10.1186/s12888-021-03642-z

Ejemplares similares